I:SPX Oct 2023 Weekly 3100.000 - INFI STOCK NEWS

Ovarian cancer poses serious challenges globally, with over 240,000 diagnoses annually. BioVaxys Technology Corp. has initiated a clinical program for BVX-0918A, aiming to address unmet needs in Stage III and IV ovarian cancer. The company plans to seek compassionate use approval in the EU and will submit a clinical trial application later this year. Additionally, they completed a preclinical program for the SARS-CoV-2 vaccine candidate BVX-0320 with promising results. Ongoing clinical trials and advancements in immunotherapy are pivotal in shaping the future of cancer treatment.

Infinity Pharmaceuticals (NASDAQ: INFI) will participate in a Fireside Chat with Andrew D’Silva from B. Riley Securities on January 20, 2021, at 10:30 am ET. The event is exclusively for institutional investors, investor relations, and company employees. A replay will be available on the Events and Presentations page post-conference. Infinity is focused on developing eganelisib, a first-in-class oral immuno-oncology treatment for cancer, currently in multiple clinical studies.

Infinity Pharmaceuticals (NASDAQ: INFI) will present data from the MARIO-275 study at the ASCO 2021 Genitourinary Cancers Symposium on February 11, 2021. This randomized Phase 2 study assesses adding eganelisib to nivolumab (Opdivo®) for patients with advanced urothelial cancer who are platinum-refractory and I/O naïve, compared to nivolumab alone. The study aims to evaluate the safety and efficacy of this combination treatment.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that CEO Adelene Perkins will present virtually at three investor conferences from January 7-14, 2021. The conferences include the 39th Annual J.P. Morgan Healthcare Conference on January 14, LifeSci Advisors Corporate Access Event from January 7-13, and H.C. Wainwright BioConnect 2021 Conference from January 11-14. One-on-one meetings will also be available. Infinity is actively developing eganelisib, an immuno-oncology candidate targeting cancer treatment through various ongoing clinical studies.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) provided an update on its Phase 2 study, MARIO-275, which evaluates eganelisib in combination with nivolumab for advanced urothelial cancer. The study included 49 patients and demonstrated a favorable safety profile, particularly benefiting those with low PD-L1 expression. The company plans to conduct a new registration-enabling study based on encouraging results and will present the MARIO-275 data at a major medical meeting in Q1 2021. Infinity ended 2020 with approximately $34.1 million in cash, anticipating sufficient funds through 2021.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) presented promising data from the MARIO-3 clinical trial for eganelisib at the SABCS 2020. This ongoing Phase 2 trial evaluates eganelisib combined with atezolizumab and nab-paclitaxel for treating unresectable advanced triple-negative breast cancer (TNBC). Results showed a 100% overall response rate in PD-L1 positive patients and 50% in PD-L1 negative patients, with significant tumor reduction. The FDA has granted Fast Track designation for eganelisib in TNBC, expediting its development.

Infinity Pharmaceuticals (NASDAQ: INFI) will conduct a conference call on December 9, 2020, at 10:00 a.m. ET to discuss clinical data from ongoing studies of eganelisib in triple-negative breast cancer (TNBC). This presentation coincides with the San Antonio Breast Cancer Symposium taking place virtually from December 8-11, 2020. Key presentations include initial data from the MARIO-3 phase II study and the ARC-2 study regarding combinations involving eganelisib and other treatments. More details and participation options are available on Infinity's website.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will present two clinical studies on eganelisib in triple negative breast cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS) from December 8-11, 2020. The MARIO-3 phase II study will showcase initial data on a triplet combination therapy involving eganelisib, atezolizumab, and nab-paclitaxel as first-line treatment for advanced TNBC. Additionally, the ARC-2 study will evaluate the efficacy and safety of etrumadenant in conjunction with pegylated liposomal doxorubicin, with presentations scheduled for December 9, 2020.

Infinity Pharmaceuticals reported its Q3 2020 financial results, highlighting an ongoing focus on its lead product, eganelisib. The company is approaching crucial data readouts across multiple clinical programs. Notably, the Independent Data Monitoring Committee (IDMC) has supported resuming enrollment in the MARIO-275 trial for advanced urothelial cancer after a dose reduction to mitigate liver enzyme elevations. Financially, Infinity reported a net loss of $9.5 million, improving from a net loss of $11.4 million in Q3 2019, with expectations of a net loss between $35 million to $45 million for 2020.